The efficacy of the H2 receptor antagonist, cimetidine, in the treatment of a patient with porphyria cutanea tarda (PCT) was evaluated. After administration of cimetidine for 2 weeks, urinary excretion of uroporphyrin (UP) and coproporphyrin (CP) was significantly decreased.
Introduction
Porphyria cutanea tarda (PCT) is a metabolic disorder of hemebiosynthesis that presents in adults and is associated with cutaneous lesions characterized clinically by mechanical fragility and blistering of light-exposed skin and biochemically by uroporphyrinuria ( 1 ) . A reduced hepatic activity of the enzyme uroporphyrinogen decarboxylase (UROD) is the biochemical defect responsible for the disease (1, 2) . Phlebotomy and chloroquine have been reported effective in the treatment of patients with PCT; these treatments need careful management due to side effects such as anemiaand hepatotoxicity, respectively (3, 4) .
Cimetidine, a histamine H2-receptor antagonist, has been reported to decrease hepatic 8-aminolevulinate synthase (ALAS) activity (5) . Wereported the first case study in which oral cimetidine in a daily dose of 800 mgwas effective in decreasing urinary excretion of 5-aminolevulinic acid (ALA)in a patient with acute intermittent prophyria (AIP) (6) . Subsequently, Yamamotoet al (7) reported that oral cimetidine also reduced the levels of erythrocyte protoporphyrin (PP) in a patient with erythropoietic protoporphyria (EPP). Wereport here that oral cimetidine treatment was also effective in suppressing both urinary porphyrin excretion and clinical symptomsin a patient with PCT.
Patient
A 6 1 -year-old male was referred to Tottori University Hospital in October 1993 with the chief complaints of dark urine and cutaneous lesions in light-exposed areas including his face, neck and hands. He had a history of alcohol intake for 40 years (average daily intake 60g). He had been diagnosed as chronic active hepatitis type C (hepatitis C virus antibody positive) at the age of 59. On admission, he was diagnosed as PCT associated with chronic hepatitis type C based on cutaneous photosensitivity and elevated urinary uroporphyrin (UP) and 7-carboxylate porphyrin levels and isocoproporphyrin excretion in stool, the biochemical hallmark of this disease ( Table 1 ). The family history study was unremarkable. Physical examination showed cutaneous hyperpigmentation, facial hypertrichosis and bulla formation on the dorsal side of both hands. Hepatomegaly was noted at 2 finger breadths in the right hypochondrium. Laboratory data on admission were as follows: peripheral (HBsAb), negative; hepatitis B core antibody (HBcAb), negative; hepatitis C virus antibody (HCV-Ab), positive; HCV-RNA, positive; indocyanine green retention rate (at 15 minutes), 12% (less than 10). Porphyrin excretion data are shown in Table 1 . Histological findings under laparoscopy showed chronic active hepatitis with cirrhosis. These findings in the patient were compatible with PCT. During two weeks of admission in the hospital, the patient stopped drinking alcohol. Coproporphyrin (CP) tended to decline, however, urinary excretion of UPremained unchanged. Oral cimetidine (800 mg daily dose) was started on the 1 4th day of admission (Fig. 1 ) . After administration ofcimetidine, urinary excretion of UP and CP decreased markedly. Urinary porphyrins did not increase by the cessation of cimetidine for 1 week. Although the readministration of cimetidine did not decrease urinary porphyrins, skin lesions improved markedly after cimetidine treatment. Serum GGT, AST, ALT and serum ferritin decreased to the normal range after readministration of cimetidine. After discharge, the patient was free of both photosensitivity and progression of liver function tests even after withdrawal of cimetidine.
Discussion
PCTis the most commonform of the porphyrias in manand is characterized by dermal photosensitivity and uroporphyrinuria (1, 2) . The precipitating factors in this disorder include iron, alcohol, certain drugs, or other environmental chemicals. The principal enzymatic defect in this disorder is URODdeficiency botomy has been carried out at the rate of 500 ml to 1,000 ml once or twice monthly, with monitoring the patient ' s hemoglobin levels (2, 3) . Treatment with chloroquine has also been reported effective in patients with PCTwhich causes depletion of UP in the liver, by forming a water-soluble complex with the porphyrin which is then excreted into urine. However,serious hepatotoxic reactions have been reported with its use (4). Due to these side effects ofphlebotomy or chloroquine, other safer therapeutic regimens for treatment of PCT are desirable (1, 2) . Cimetidine, a histamine H2 receptor antagonist, has been used in the treatment of peptic ulcers. Cimetidine has been reported to impair the elimination of drugs, which are metabolized by microsomal monooxygenases in the liver, probably through binding to the heme moiety of cytochrome P450 (8-1 1) . This drug has also been shown to inhibit hepatic ALAS activity and heme oxygenase (5) .
Wehave reported the clinical usefulness of cimetidine in patients with AIP both in remission and in relapse (6, 12) , and these findings were subsequently, confirmed by others (13) . Recently, Yamamoto et al also reported that cimetidine reduced the erythrocyte PP concentration in a patient with EPP (7). In this report, oral administration of cimetidine was found useful in reducing urinary excretion of UP and CP, and serum GGT, AST, ALTand serum ferritin in a patient with PCT. Furthermore,clinical symptoms such as photosensitivity improved soon after the initiation of cimetidine in the patient. Readministration of cimetidine, however, had no further effect on urinary porphyrin levels. This was probably due to the fact that, unlike AIP, the hepatic ALASactivity is not elevated in PCT (14) . Unlike the case of acute hepatic porphyrias, resolution of porphyrin elevation in this patient was observed only after a long period of treatment with cimetidine, e.g., 6 weeks. Twoother important factors contributing to porphyrin metabolism in PCTcannot be completely excluded in this case. First, alcohol plays a major role in precipitating PCT, and in this case, there was a history of long-term excessive intake of alcohol. The withdrawal of alcohol may thus play a role to improve porphyrin metabolism. Secondly, the excess of hepatocellular iron in PCT may influence porphyrin metabolism. The observed drop in serum ferritin levels thus contributed to the improvement of porphyrin metabolism. It should be noted that there are marked differences in the length of period to reach remission amongdifferent porphyrias. It is unclear whether this difference is due to different types of porphyrias, or due to different individuals; and more studies are needed to elucidate this question. In conclusion, cimetidine may also be useful in the treatment ofPCT, in addition to its proven usefulness in AIP and EPP.
